二甲双胍联合罗格列酮对2型糖尿病患者可溶性细胞黏附分子的影响

目的:探讨二甲双胍联合罗格列酮对2型糖尿病患者可溶性细胞黏附分子表达的影响。方法:60例2型糖尿病患者分为二甲双胍组(A组)和二甲双胍加罗格列酮组(B组),每组各30例,治疗24周。分别检测治疗前及治疗后12、24周空腹血糖、血脂、血清可溶性细胞间黏附分子-1(sICAM-1)和可溶性血管细胞间黏附分子-1(sVCAM-1)的水平。结果:两组患者经治疗12周后血糖均不同程度改善,24周后B组血糖降低水平优于A组,差异有统计学意义(P﹤0.05)。两组患者血清甘油三酯、胆固醇均较治疗前下降,仅B组高密度脂蛋白胆固醇升高,差异有统计学意义(P﹤0.05)。治疗24周后,B组血清sICAM-1和sVCAM-1表达水平低于A组,差异有统计学意义(P﹤0.05)。结论:二甲双胍联合罗格列酮治疗可持续稳定改善糖尿病患者的代谢综合征,同时减少患者血浆黏附分子的表达,有助于改善或延缓糖尿病合并动脉粥样硬化的发生。

The influence of metformin plus rosiglitazone on cell adhesionmolecules in type 2 diabetic patients

【Abstract】Objective To investigate the influences of metformin plus rosiglitazone on cell adhesionmolecules in type 2 diabetic patients. Methods 60 type 2 diabetic patients were randomly divided into the metformin group（A）、metformin plus rosiglitazone group(B).Each group has 30 subjects . The concentration of lipids and FPG were measured before and after 12-week and 24- week treatment. Soluble vascular cell adhesion molecule-1(sVCAM-1) and soluble intercellular adhesion molecules-1 (sICAM-1) were determined by ELISA also. Results Serum FPG in two groups decreased significantly after 12-week and 24-week treatment. Serum FPG in B group was more decreased than A group at 24 weeks（P﹤0.05）.Serum TG and TC in two groups decreased and HDL-C in B group increased after 12-week treatment（P﹤0.05）. The serum sVCAM-1 and sICAM-1 in B group were more reduced than A group after 24-week treatment（P﹤0.05）.Conclusion Metformin plus rosiglitazone might to improve metabolic syndrome and reduce the expression of sVCAM-1 and sICAM-1 to delay the advancement of atherosclerosis in type 2 diabetic patients.